tetano
Editor, Senior Moderator
Mol Ther
. 2021 Aug 5;S1525-0016(21)00395-6.
doi: 10.1016/j.ymthe.2021.08.001. Online ahead of print.
A comprehensive analysis of the efficacy and safety of COVID-19 vaccines
Changjing Cai[SUP] 1 [/SUP], Yinghui Peng[SUP] 1 [/SUP], Edward Shen[SUP] 2 [/SUP], Qiaoqiao Huang[SUP] 1 [/SUP], Yihong Chen[SUP] 1 [/SUP], Ping Liu[SUP] 1 [/SUP], Cao Guo[SUP] 1 [/SUP], Ziyang Feng[SUP] 1 [/SUP], Le Gao[SUP] 1 [/SUP], Xiangyang Zhang[SUP] 1 [/SUP], Yan Gao[SUP] 1 [/SUP], Yihan Liu[SUP] 1 [/SUP], Ying Han[SUP] 3 [/SUP], Shan Zeng[SUP] 4 [/SUP], Hong Shen[SUP] 5 [/SUP]
Affiliations
Abstract
The numbers of cases and deaths from coronavirus disease 2019 (COVID-19) are continuously increasing. Many people are concerned about the efficacy and safety of the COVID-19 vaccines. We performed a comprehensive analysis of the published trials of COVID-19 vaccines and the real-world data from the Vaccine Adverse Event Reporting System. Globally, our research found that the efficacy of all vaccines exceeded 70%, and RNA-based vaccines had the highest efficacy of 94.29%; moreover, Black or African American people, young people and males may experience greater vaccine efficacy. The spectrum of vaccine-related adverse drug reactions (ADRs) is extremely broad, the most frequent ADRs are pain, fatigue and headache. Most ADRs are tolerable and are mainly grade 1 or 2 in severity. Some severe ADRs have been identified (thromboembolic events: 21-75 cases per million doses; myocarditis/pericarditis: 2-3 cases per million doses). In summary, vaccines are a powerful tool that can be used to control the COVID-19 pandemic, with high efficacy and tolerable ADRs. In addition, the spectrum of ADRs associated with the vaccines is broad, and most of the reactions appear within a week, while some may be delayed. Therefore, ADRs after vaccination need to be identified and addressed in a timely manner.
. 2021 Aug 5;S1525-0016(21)00395-6.
doi: 10.1016/j.ymthe.2021.08.001. Online ahead of print.
A comprehensive analysis of the efficacy and safety of COVID-19 vaccines
Changjing Cai[SUP] 1 [/SUP], Yinghui Peng[SUP] 1 [/SUP], Edward Shen[SUP] 2 [/SUP], Qiaoqiao Huang[SUP] 1 [/SUP], Yihong Chen[SUP] 1 [/SUP], Ping Liu[SUP] 1 [/SUP], Cao Guo[SUP] 1 [/SUP], Ziyang Feng[SUP] 1 [/SUP], Le Gao[SUP] 1 [/SUP], Xiangyang Zhang[SUP] 1 [/SUP], Yan Gao[SUP] 1 [/SUP], Yihan Liu[SUP] 1 [/SUP], Ying Han[SUP] 3 [/SUP], Shan Zeng[SUP] 4 [/SUP], Hong Shen[SUP] 5 [/SUP]
Affiliations
- PMID: 34365034
- DOI: 10.1016/j.ymthe.2021.08.001
Abstract
The numbers of cases and deaths from coronavirus disease 2019 (COVID-19) are continuously increasing. Many people are concerned about the efficacy and safety of the COVID-19 vaccines. We performed a comprehensive analysis of the published trials of COVID-19 vaccines and the real-world data from the Vaccine Adverse Event Reporting System. Globally, our research found that the efficacy of all vaccines exceeded 70%, and RNA-based vaccines had the highest efficacy of 94.29%; moreover, Black or African American people, young people and males may experience greater vaccine efficacy. The spectrum of vaccine-related adverse drug reactions (ADRs) is extremely broad, the most frequent ADRs are pain, fatigue and headache. Most ADRs are tolerable and are mainly grade 1 or 2 in severity. Some severe ADRs have been identified (thromboembolic events: 21-75 cases per million doses; myocarditis/pericarditis: 2-3 cases per million doses). In summary, vaccines are a powerful tool that can be used to control the COVID-19 pandemic, with high efficacy and tolerable ADRs. In addition, the spectrum of ADRs associated with the vaccines is broad, and most of the reactions appear within a week, while some may be delayed. Therefore, ADRs after vaccination need to be identified and addressed in a timely manner.